Preservation of β-Cell Function: The Key to Diabetes Prevention
The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Abstract
CONTEXT: The Centers for Disease Control and Prevention estimates that there are approximately 79,000,000 individuals in the United States with prediabetes [impaired glucose tolerance (IGT) and/or impaired fasting glucose] and that approximately 40-50% will progress to type 2 diabetes mellitus (T2DM) during their lifetime. Therefore, treatment of high-risk IGT individuals to prevent T2DM has important medical, economic, social, and human implications. Individuals in the upper tertile of IGT are maximally/near-maximally insulin resistant, have lost 70-80% of their β-cell function, and have approximately a 10% incidence of diabetic retinopathy. Therefore, preservation of the remaining 20-30% of β-cell function is critical to prevent future development of T2DM. EVIDENCE ACQUISITION: We searched MEDLINE from 2000 to the present to identify placebo-controlled trials in which individuals with IGT received pharmacological therapy to prevent progression to diabetes. EVIDENCE SYNTHESIS: Lifestyle modification reduces IGT conversion to T2DM, but it is difficult to implement and maintain. Moreover, 40-50% of IGT subjects progress to T2DM despite weight loss. In contrast, pharmacological intervention with medications that reverse known pathophysiological abnormalities (β-cell dysfunction and insulin resistance) uniformly prevents IGT progression to T2DM. Thiazolidinediones reduce IGT conversion to diabetes by approximately 50-70%. Metformin in the U.S. Diabetes Prevention Program reduced the development of T2DM by 31% and has been recommended by the American Diabetes Association. Because glucagon-like peptide-1 analogs augment insulin secretion, preserve β-cell function, and promote weight loss, they may be efficacious in preventing IGT progression to T2DM. CONCLUSION: Pharmacological intervention with a variety of agents (thiazolidinediones, metformin, acarbose, glucagon-like peptide-1 analogs) consistently reduces the rate of conversion of IGT to T2DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Fasting plasma glucose values are determined by endogenous glucose production (EGP) that is mostly dependent on the liver.”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
In the citing paper
“The product of EGP and fasting insulin is used as a marker of hepatic insulin resistance and it shows a relatively strong relationship with fasting glycaemia.38,39,45”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
In the citing paper
“Both IFG and IGT subjects present with insulin resistance, however the site of insulin resistance is different: High hepatic insulin resistance is a typical finding in IFG with almost normal values in skeletal muscle.38,39,45 In IGT, the main site of insulin resistance is the muscle with only modest changes in liver insulin sensitivity.37,38”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
In the citing paper
“The primary aim of lifestyle interventions is to prevent or delay the development of type 2 diabetes and its complications13,45 by targeting obesity and physical inactivity, the two most important modifiable risk factors of diabetes development.3,25”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
In the citing paper
“The glitazones, such as troglitazone, rosiglitazone and pioglitazone, act through the PPAR-γ receptor by increasing hepatic and peripheral insulin sensitivity and preserving insulin secretion.45,95”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Cited by
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citationMetformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,349
Mitochondrial and metabolic dysfunction in ageing and age-related diseases
Amorim, J. A., Coppotelli, G., Rolo, A. P., Palmeira, C. M., Ross, J. M., & Sinclair, D. A. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00626-7 · Cited by 990
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier
Divakaruni, A. S., Wiley, S. E., Rogers, G. W., Andreyev, A. Y., Petrosyan, S., Loviscach, M., Wall, E. A., Yadava, N., Heuck, A. P., Ferrick, D. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303360110 · Cited by 308
“Thiazolidinediones (TZDs) are the most effective agents for preventing the progression from hyperglycemia to type 2 diabetes (6), and the increasingly appreciated link between dysregulated glucose metabolism and human disease has triggered the repurposing of pioglitazone to treat neurodegenerative conditions and certa…”
Background
Metadata
- Authors
- DeFronzo, R. A., & Abdul-Ghani, M. A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- ORCID
- DeFronzo, Ralph A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-08
- Volume
- 96
- Issue
- 8
- Pages
- 2354-2366
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2131616886
- Cited by
- 247
- References
- 131
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 15 · 2023: 13 · 2022: 7 · 2021: 11 · 2020: 23 · 2019: 12 · 2018: 18 · 2017: 16 · 2016: 19 · 2015: 14 · 2014: 31 · 2013: 28 · 2012: 17
- FWCI
- 20.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 2 diabetes prevention, impaired glucose tolerance, beta-cell preservation, insulin resistance, thiazolidinediones, metformin, glucagon-like peptide-1 analogues, acarbose, lifestyle modification, pharmacological interventions, prediabetes
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Prediabetic State, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preservation of β-Cell Function: The Key to Diabetes Prevention. https://app.cochat.ai/papers/10.1210/jc.2011-0246
- The paper
- DeFronzo, R. A., & Abdul-Ghani, M. A. (2011). Preservation of β-Cell Function: The Key to Diabetes Prevention. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2011-0246
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.